Cultural and ethical differences between Western and East Asian standards must be considered in order to make the International Conference for Harmonization (ICH) work. This paper covers six broad ethical rules of East Asian society, implications for the ICH process, and concerns that still need to be addressed in the ICH guideline.
GoodsonRL. Good Clinical Practices: Past, Present, and Future. Qual Assur.1995;4(1):60–67.
2.
BeckerC. Mass Nouns, Truth, and Causal Agency in Japanese Language: Reasons behind the Differences between Japanese and Western Philosophy. Area Studies Tsukuba.1991, 9:93–117; repr. in Cross-Cultural Communication: East and West. HI ed. Paul Fendos. Tainan: Tai Ch'eng Publishing; 1991.
3.
FettersMD. Nemawashi Essential for Conducting Research in Japan. Social Sci Med.1995;41(3): 375–381.
4.
NorbeckELockM. Health, Illness, and Medical Care in Japan.Honolulu: University of Hawaii Press; 1987.
5.
YantadaA. The Status and Problems of Phase III Clinical Trials of New Anti-Tumor Drugs: The Pharmaceutical Company's View. Gan to Kagaku Ryoho.1995;22:(3):323–327.
6.
BarkerS. Deaths Prompt Calls for Drug Control Review. Nature.1995;378(6556):431.
7.
ICH EWG E6: Good Clinical Practice: Consolidated Guideline. May 1, 1996.
8.
EdgarHRothmanDJ. The Institutional Review Board and Beyond. Milbank Quart.1995;73:4:489–506.
HattoriH. The Patient's Right to Information in Japan. Social Sci Med.1991;32:9:1007–1016.
12.
NagayamaK. Informed Consent from Psychotic Patients with Cancer Regarding Surgical Operation. Seishin Igaku/Clinical Psychiatry.1994;36: (6):625–632.
13.
MinogueBP. Individual Autonomy and the Double-Blind Controlled Experiment: the Case of Desperate Volunteers. J Med Philos.1995;20(1): 43–55.
14.
Kang-YumE. Cross-Cultural Miscommunication: Chinese Herbal Medicines. Hastings Center Report. May-June, 199626:3:46.
15.
CuppensHCassimanJJ. A Quality Control Study of CFTR Mutation Screening in 40 Different European Laboratories. Europ J Human Genetics.1995;3:4: 235–245.
16.
PurvesD. Genotoxicity Testing: Current Practices and Strategies. Mutagenesis.1995;10:(4):297–312.
17.
GuestR. Japan Criticised for Unsafe Drug Licenses. Br Med J.1995;311(7019):1521–1522.
18.
AsaiAFukuharaS. Attitudes of Japanese and Japanese-American Physicians Towards Life-Sustaining Treatment. Lancet.1995;346(8971):327–328.
19.
Infected Blood in Japan.Nature.1996;380(6569):1.
20.
LeporeP. The FDA's Fraud Policy and Ethical Concerns. Qual Assur.1995;4(1):8–11.
21.
O'NeillRT. Statistical Concepts in the Planning and Evaluation of Drug Safety from Clinical Trials in Drug Development. Stat Med.1995;14(9–10): 117–27.
22.
Martinez-Cairo-CuetoSAmato-MartinezJD. Los Principios Eticos de la Investigacion Medica en Seres Humanos. Gac Med Mex.1995;131(2):251–257.
